Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

Nico Gagelmann(Universität Hamburg), Annalisa Ruggeri(Inserm), Laurent Garderet(Inserm), Meral Beksaç(Ankara University), Kate Morgan(Association des Operateurs Postaux Publics Europeens), Stefan Schönland(Heidelberg University), Michelle Kenyon(Pfizer (United States)), Natacha Bolaños(HOPE Clinic), Hans Scheurer(European Federation of Allergy and Airways Diseases Patients Associations), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), John Murray(Tallaght University Hospital), Silvia Montoto(Queen Mary University of London), Patrick Hayden, Donal P. McLornan(King's College London)
The Lancet Haematology
September 26, 2022
10.1016/s2352-3026(22)00226-5
Cited by 48

Related Papers

International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2015|740
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721